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Introduction: Hypercalcemia is one of the most common metabolic abnormalities encountered in any form of
malignancy. Hypocalcemia, however, is a rare manifestation, especially in cancers with bone involvement. Here we
present a case of hypocalcemia in a patient with multiple myeloma that was refractory to treatment.
Case presentation: A 73-year-old African American woman recently diagnosed with multiple myeloma, presented
with a 2-day history of fever, vomiting and hypocalcemia. Ten days prior to admission she received zoledronic acid,
Velcade® (bortezomib), Revlimid® (lenalidomide) and dexamethasone. Treatment was started with intravenous
antibiotics and calcium gluconate boluses. After 24 hours of treatment her calcium level became undetectable
(<5mg/dL). Continuous intravenous calcium gluconate infusions in addition to boluses were started. She
remained persistently hypocalcemic and eventually developed tonic–clonic seizures. Vitamin D levels were
found to be low and intravenous paricalcitol was initiated, which improved her calcium level.
Conclusions: Underlying vitamin D deficiency can precipitate severe hypocalcemia in patients with multiple
myeloma receiving bisphosphonates. This warrants baseline screening for vitamin D deficiency in these patients.
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Multiple myeloma (MM) is a malignant proliferation of
plasma cells, characterized by the presence of monoclo-
nal immunoglobulin in serum and urine. Zoledronic acid
(ZA) is a standard part of the treatment, as patients with
MM usually have hypercalcemia secondary to bone de-
struction. However, some cases of hypocalcemia have
been reported when bisphosphonates were used in pa-
tients with vitamin D deficiency [1-3]. Our case differs
in the fact that our patient with MM developed severe
hypocalcemia just after receiving her first dose of ZA.
Case presentation
A 73-year-old African American woman with diabetes
mellitus, hypertension, and recently diagnosed immuno-
globulin G MM, presented with 2 days’ history of fever,
nausea, vomiting and dizziness. She was found to be* Correspondence: adrianaldave@uabmc.edu
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bated for airway protection. She was febrile (39.33°C,
102.8°F), but hemodynamically stable. She demonstrated
mild respiratory distress, had rales and wheezes on auscul-
tation, and edema in both lower extremities. Initial labora-
tory results (Table 1) revealed pancytopenia, elevated
creatinine and corrected calcium of 7.3mg/dL, other elec-
trolytes were within normal limits. A chest radiograph re-
vealed cardiomegaly and pulmonary edema. Ten days prior
to admission she received one dose of ZA, three doses of
bortezomib, and seven doses of daily lenalidomide in
addition to weekly dexamethasone. A clinical diagnosis of
neutropenic fever, acute renal failure and severe hypocalce-
mia was made. Treatment was started with intravenous
vancomycin and cefepime. She was also given calcium glu-
conate boluses for her hypocalcemia.
Even after 24 hours of treatment, her mental status
did not improve. She remained febrile, her kidney func-
tions worsened, and her calcium level became undetect-
able (<5mg/dL) and ionized calcium was 0.66mmol/L
(see Table 1). She was started on continuous intravenousioMed Central Ltd. This is an Open Access article distributed under the terms of
tp://creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Table 1 Comparison of laboratory parameters at first chemotherapy dose, admission and hospital stay
CHEMISTRY Biochemistry 1 day
before chemotherapy






Corrected calcium (mg/dL) 10.3 7.3 <5 (undetectable) 8.4
Ionized calcium (mmol/L) – – 0.66 1.13
Creatinine (mg/dL) 0.99 1.69 8 4.8
Glomerular filtration rate
(mL/minute/1.73m2)
>60 36 6 –
Vitamin D (ng/mL) – – 13 –
Laboratory results not done.
Noriega Aldave and Jaiswal Journal of Medical Case Reports 2014, 8:353 Page 2 of 3
http://www.jmedicalcasereports.com/content/8/1/353calcium gluconate infusion in addition to boluses, which
still did not increase her calcium levels. We then tested for
vitamin D levels which were found to be low (13ng/mL).
The value of vitamin D was measured on the day in which
renal function was most impaired (creatinine 8mg/dL).
Intravenous paricalcitol was initiated, which did improve
her calcium level, but, it did not revert to normal. Despite
aggressive calcium replacement she remained persistently
hypocalcemic and eventually developed tonic–clonic sei-
zures. An electrocardiogram revealed a QT interval of
500ms using Bazett’s formula. Her neuroimaging, however,
was normal except for several small calvarium lytic lesions
(Figure 1). Her family eventually made the decision to focus
on comfort measures only, following which, she had a car-
diac arrest and died on hospital day 17.Figure 1 Computed tomography of brain (bone window).
Computed tomography brain scan showing multiple lytic lesions in
the calvarium (arrow).Discussion
ZA is a long-acting bisphosphonate used for supportive
therapy in MM and bone metastasis. It has a safety profile
similar to that of pamidronate, but because of ease of ad-
ministration, it is preferred over the latter. In the long run,
both pamidronate and ZA have been shown to reduce skel-
etal related events, and decrease need for irradiation [4].
Bisphosphonates are generally well tolerated, although
they are occasionally associated with adverse events
namely hypocalcemia, nephrotoxicity, pancytopenia and
osteonecrosis [5-7].
Renal dysfunction is an undesired side effect that can
occur after intravenous infusion of bisphosphonate [5]. In
this case, her kidney functions were normal before starting
chemotherapy, but a week after initiating ZA, she devel-
oped acute renal failure. This may also have been exacer-
bated by the MM nephropathy, but arguably her kidney
functions had remained stable from the time of the diag-
nosis until she got her first dose of ZA.
All bisphosphonates can cause hypocalcemia, regard-
less of their method of administration, although this is
infrequently found to be a clinically symptomatic prob-
lem [7,8]. Of note, symptomatic hypocalcemia after ZA
is rarely reported.
Hypovitaminosis D and concurrent dexamethasone
and ZA administration have been identified as independ-
ent risk factors for severe hypocalcemia when metastatic
tumors are treated with ZA [9]. Corticosteroids decrease
blood calcium levels by suppression of intestinal calcium
absorption, depression of vitamin D activity and re-
absorption of calcium in renal tubules.
There are some case reports about patients with MM
with unrecognized vitamin D deficiency, who developed
hypocalcemia following ZA that improved only after
vitamin D replacement [1]; as can also be appreciated in
this case.
Conclusions
Some studies have reported up to 150% increase in mor-
tality, among critical care unit patients, with ionized
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ionized calcium of 0.66mmol/L. Unfortunately, the level
of vitamin D is not part of routine screening in patients
receiving bisphosphonates for cancers. This case there-
fore serves to remind us that careful clinical and bio-
chemical evaluation is required before administration of
bisphosphonates in cancers to avoid undesired side ef-
fects; and vitamin D levels should be a part of screening
before administering more potent and longer acting
bisphosphonates, such as ZA.
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